# ![@oneortwo1234 Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1961960280159592448.png) @oneortwo1234 oneortwo1234

oneortwo1234 posts on X about $ocul, $apls, wet, up to the most. They currently have [--] followers and [--] posts still getting attention that total [---] engagements in the last [--] hours.

### Engagements: [---] [#](/creator/twitter::1961960280159592448/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1961960280159592448/c:line/m:interactions.svg)

- [--] Week [-----] -8.60%

### Mentions: [--] [#](/creator/twitter::1961960280159592448/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1961960280159592448/c:line/m:posts_active.svg)


### Followers: [--] [#](/creator/twitter::1961960280159592448/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1961960280159592448/c:line/m:followers.svg)

- [--] Week [--] no change

### CreatorRank: [---------] [#](/creator/twitter::1961960280159592448/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1961960280159592448/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  [technology brands](/list/technology-brands) 

**Social topic influence**
[$ocul](/topic/$ocul) #36, [$apls](/topic/$apls), [wet](/topic/wet), [up to](/topic/up-to), [eye](/topic/eye), [cloud](/topic/cloud), [events](/topic/events), [selling pressure](/topic/selling-pressure), [hope](/topic/hope), [weakness](/topic/weakness)

**Top accounts mentioned or mentioned by**
[@statnews](/creator/undefined) [@retinatoday](/creator/undefined) [@zipjet](/creator/undefined) [@tomsilver39](/creator/undefined) [@paperboy2009](/creator/undefined) [@george_deng7](/creator/undefined)

**Top assets mentioned**
[Ocular Therapeutix, Inc. (OCUL)](/topic/$ocul) [Apellis Pharmaceuticals, Inc. Common Stock (APLS)](/topic/$apls)
### Top Social Posts
Top posts by engagements in the last [--] hours

"$ocul Fidelity reports a 15% stake https://archive.fast-edgar.com/20251105/AQLZE622C222AZZ2222B2ZZZK4SNZ232PW72/ https://archive.fast-edgar.com/20251105/AQLZE622C222AZZ2222B2ZZZK4SNZ232PW72/"  
[X Link](https://x.com/oneortwo1234/status/1986113823623815587)  2025-11-05T16:50Z [--] followers, [--] engagements


"$apls "we have not seen any side effects due to Syfovre." This interview is huge We all know that Syfovre is more effective than Izervay but there was always a cloud surrounding potential side effects. This interview puts that notion to rest. https://europe.ophthalmologytimes.com/view/q-a-jay-chhablani-discusses-analysis-of-retinal-vasculitis-events-with-intravitreal-agents https://europe.ophthalmologytimes.com/view/q-a-jay-chhablani-discusses-analysis-of-retinal-vasculitis-events-with-intravitreal-agents"  
[X Link](https://x.com/anyuser/status/1989777906911039503)  2025-11-15T19:29Z [--] followers, [--] engagements


"$apls "since October [----] the last case of retinal vasculitis which was reported due to Syfovre that was the last case. And after that there have been no events.""  
[X Link](https://x.com/anyuser/status/1989787303091605755)  2025-11-15T20:07Z [--] followers, [--] engagements


"@RetinaToday $apls"  
[X Link](https://x.com/oneortwo1234/status/2010777565921685656)  2026-01-12T18:15Z [--] followers, [--] engagements


"$apls https://www.insidermonkey.com/blog/11-best-high-short-interest-stocks-with-biggest-upside-potential-1681595/ https://www.insidermonkey.com/blog/11-best-high-short-interest-stocks-with-biggest-upside-potential-1681595/"  
[X Link](https://x.com/anyuser/status/2016509531870671173)  2026-01-28T13:51Z [--] followers, [--] engagements


"$ocul Could the weakness be because a fund is exiting their position Hope that the selling pressure abates and Ocul can rally"  
[X Link](https://x.com/anyuser/status/2017333285538402658)  2026-01-30T20:25Z [--] followers, [---] engagements


"$ocul https://www.insidermonkey.com/blog/bofa-bullish-on-ocular-therapeutix-ocul-as-axpaxli-targets-superiority-label-and-faster-regulatory-path-in-wet-amd-1667804/ https://www.insidermonkey.com/blog/bofa-bullish-on-ocular-therapeutix-ocul-as-axpaxli-targets-superiority-label-and-faster-regulatory-path-in-wet-amd-1667804/"  
[X Link](https://x.com/oneortwo1234/status/2006407278597980464)  2025-12-31T16:49Z [--] followers, [---] engagements


"https://www.insidermonkey.com/blog/bofa-bullish-on-ocular-therapeutix-ocul-as-axpaxli-targets-superiority-label-and-faster-regulatory-path-in-wet-amd-1667804/ https://www.insidermonkey.com/blog/bofa-bullish-on-ocular-therapeutix-ocul-as-axpaxli-targets-superiority-label-and-faster-regulatory-path-in-wet-amd-1667804/"  
[X Link](https://x.com/oneortwo1234/status/2006408228100321551)  2025-12-31T16:52Z [--] followers, [--] engagements


"$ocul Robinson:"My experience leading the launch of EYLEA showed me firsthand how meaningful innovation coupled with disciplined execution can reshape treatment paradigms and create entirely new standards of care. I see similar potential with https://www.pharmalive.com/pharma-people-on-the-move-winter-2026-roundup/ https://www.pharmalive.com/pharma-people-on-the-move-winter-2026-roundup/"  
[X Link](https://x.com/anyuser/status/2018766452296167767)  2026-02-03T19:20Z [--] followers, [----] engagements


"$ocul Looks like there's an update on Helios DR in addition to SOL-1 (Phase [--] wet AMD) superiority trial at the Macula Society. https://www.xcdsystem.com/maculasociety/program/IUDYmFD/index.cfmpgid=416 https://www.xcdsystem.com/maculasociety/program/IUDYmFD/index.cfmpgid=416"  
[X Link](https://x.com/anyuser/status/2019458680245063977)  2026-02-05T17:10Z [--] followers, [---] engagements


"$ocul The Company further intends to leverage the 505(b)(2)approval pathway which could potentially shorten the NDA review timeline for AXPAXLI by up to two months. https://investors.ocutx.com/node/14586/html https://investors.ocutx.com/node/14586/html"  
[X Link](https://x.com/anyuser/status/2019396763803873390)  2026-02-05T13:04Z [--] followers, [---] engagements


"@zipjet $ocul All this hoopla has increased the odds of the data being unveiled in the Feb 16-20 timeframe"  
[X Link](https://x.com/oneortwo1234/status/2019497061649895526)  2026-02-05T19:43Z [--] followers, [---] engagements


"@tomsilver39 $ocul BoA must have strong conviction about the impending data it's remarkable that they not only mention Ocul as one of their top Buys they raise the PO"  
[X Link](https://x.com/oneortwo1234/status/2019599309910561129)  2026-02-06T02:29Z [--] followers, [---] engagements


"$ocul On December [--] [----] Ocular Therapeutix announced it will enter a quiet period starting December [--] [----] as it prepares for database lock of its SOL-1 Phase [--] clinical trial of AXPAXLI https://www.theglobeandmail.com/investing/markets/stocks/OCUL-Q/pressreleases/36722510/ocular-therapeutix-enters-quiet-period-ahead-of-sol-1-milestone/ https://www.theglobeandmail.com/investing/markets/stocks/OCUL-Q/pressreleases/36722510/ocular-therapeutix-enters-quiet-period-ahead-of-sol-1-milestone/"  
[X Link](https://x.com/anyuser/status/2003866113038504400)  2025-12-24T16:31Z [--] followers, [---] engagements


"$ocul Ocular Therapeutix faces looming test of a more durable eye treatment via @statnews https://www.statnews.com/2026/01/08/ocular-therapeutix-wet-amd-axpaxli/ https://www.statnews.com/2026/01/08/ocular-therapeutix-wet-amd-axpaxli/"  
[X Link](https://x.com/oneortwo1234/status/2009251060896964644)  2026-01-08T13:09Z [--] followers, [---] engagements


"$apls https://press.spglobal.com/index.phps=2429&item=136445 https://press.spglobal.com/index.phps=2429&item=136445"  
[X Link](https://x.com/oneortwo1234/status/2016335492988514686)  2026-01-28T02:20Z [--] followers, [--] engagements


"$ocul Ocular Therapeutix is nearing a pivotal wet AMD readout for its Axpaxli which is administered less frequently at six months between doses. Vabysmo allows for treatment intervals of up to four months. https://www.fiercepharma.com/pharma/roche-eyes-busy-2026-vabysmo-undershoots-targets-tecentriq-fails-early-lung-cancer-study https://www.fiercepharma.com/pharma/roche-eyes-busy-2026-vabysmo-undershoots-targets-tecentriq-fails-early-lung-cancer-study"  
[X Link](https://x.com/anyuser/status/2017081312255881357)  2026-01-30T03:43Z [--] followers, [----] engagements


"$ocul RBC projects potential upside of more than 100% for OCUL https://www.investing.com/news/analyst-ratings/rbc-capital-reiterates-outperform-rating-on-ocular-therapeutix-stock-93CH-4491011 https://www.investing.com/news/analyst-ratings/rbc-capital-reiterates-outperform-rating-on-ocular-therapeutix-stock-93CH-4491011"  
[X Link](https://x.com/oneortwo1234/status/2019823157025423448)  2026-02-06T17:19Z [--] followers, [---] engagements


"$ocul https://www.stocktitan.net/sec-filings/OCUL/schedule-13g-a-ocular-therapeutix-inc-amended-passive-investment-disc-25d1f76d2f7d.html https://www.stocktitan.net/sec-filings/OCUL/schedule-13g-a-ocular-therapeutix-inc-amended-passive-investment-disc-25d1f76d2f7d.html"  
[X Link](https://x.com/oneortwo1234/status/2021254417530401263)  2026-02-10T16:06Z [--] followers, [---] engagements


"$ocul Ocular Therapeutix Strategy & AXPAXLI Outlook https://www.hdinresearch.com/news/835#::text=*%20AXPAXLI%20(OTX%2DTKI)%20Market%20Potential%3Adata%20suggests%20a%206%2D9%20month https://www.hdinresearch.com/news/835#::text=*%20AXPAXLI%20(OTX%2DTKI)%20Market%20Potential%3Adata%20suggests%20a%206%2D9%20month"  
[X Link](https://x.com/anyuser/status/2022325785940369883)  2026-02-13T15:03Z [--] followers, [---] engagements


"$ocul Ocular Therapeutix Strategy & AXPAXLI Outlook https://www.hdinresearch.com/news/835#::text=*%20AXPAXLI%20(OTX%2DTKI)%20Market%20Potential%3Adata%20suggests%20a%206%2D9%20month https://www.hdinresearch.com/news/835#::text=*%20AXPAXLI%20(OTX%2DTKI)%20Market%20Potential%3Adata%20suggests%20a%206%2D9%20month"  
[X Link](https://x.com/anyuser/status/2022325785940369883)  2026-02-13T15:03Z [--] followers, [---] engagements


"$ocul https://www.stocktitan.net/sec-filings/OCUL/schedule-13g-a-ocular-therapeutix-inc-amended-passive-investment-disc-25d1f76d2f7d.html https://www.stocktitan.net/sec-filings/OCUL/schedule-13g-a-ocular-therapeutix-inc-amended-passive-investment-disc-25d1f76d2f7d.html"  
[X Link](https://x.com/oneortwo1234/status/2021254417530401263)  2026-02-10T16:06Z [--] followers, [---] engagements


"5.13% stake per latest disclosure http://archive.fast-edgar.com/20260210/AT22M22CZ22CSJK222222ZO2TUJHIZ223282/ http://archive.fast-edgar.com/20260210/AT22M22CZ22CSJK222222ZO2TUJHIZ223282/"  
[X Link](https://x.com/anyuser/status/2021344398848688246)  2026-02-10T22:03Z [--] followers, [--] engagements


"$ocul RBC projects potential upside of more than 100% for OCUL https://www.investing.com/news/analyst-ratings/rbc-capital-reiterates-outperform-rating-on-ocular-therapeutix-stock-93CH-4491011 https://www.investing.com/news/analyst-ratings/rbc-capital-reiterates-outperform-rating-on-ocular-therapeutix-stock-93CH-4491011"  
[X Link](https://x.com/oneortwo1234/status/2019823157025423448)  2026-02-06T17:19Z [--] followers, [---] engagements


"$ocul Looks like there's an update on Helios DR in addition to SOL-1 (Phase [--] wet AMD) superiority trial at the Macula Society. https://www.xcdsystem.com/maculasociety/program/IUDYmFD/index.cfmpgid=416 https://www.xcdsystem.com/maculasociety/program/IUDYmFD/index.cfmpgid=416"  
[X Link](https://x.com/anyuser/status/2019458680245063977)  2026-02-05T17:10Z [--] followers, [---] engagements


"$ocul The Company further intends to leverage the 505(b)(2)approval pathway which could potentially shorten the NDA review timeline for AXPAXLI by up to two months. https://investors.ocutx.com/node/14586/html https://investors.ocutx.com/node/14586/html"  
[X Link](https://x.com/anyuser/status/2019396763803873390)  2026-02-05T13:04Z [--] followers, [---] engagements


"$ocul Robinson:"My experience leading the launch of EYLEA showed me firsthand how meaningful innovation coupled with disciplined execution can reshape treatment paradigms and create entirely new standards of care. I see similar potential with https://www.pharmalive.com/pharma-people-on-the-move-winter-2026-roundup/ https://www.pharmalive.com/pharma-people-on-the-move-winter-2026-roundup/"  
[X Link](https://x.com/anyuser/status/2018766452296167767)  2026-02-03T19:20Z [--] followers, [----] engagements


"$ocul Could the weakness be because a fund is exiting their position Hope that the selling pressure abates and Ocul can rally"  
[X Link](https://x.com/anyuser/status/2017333285538402658)  2026-01-30T20:25Z [--] followers, [---] engagements


"$ocul Ocular Therapeutix is nearing a pivotal wet AMD readout for its Axpaxli which is administered less frequently at six months between doses. Vabysmo allows for treatment intervals of up to four months. https://www.fiercepharma.com/pharma/roche-eyes-busy-2026-vabysmo-undershoots-targets-tecentriq-fails-early-lung-cancer-study https://www.fiercepharma.com/pharma/roche-eyes-busy-2026-vabysmo-undershoots-targets-tecentriq-fails-early-lung-cancer-study"  
[X Link](https://x.com/anyuser/status/2017081312255881357)  2026-01-30T03:43Z [--] followers, [----] engagements


"$apls https://www.insidermonkey.com/blog/11-best-high-short-interest-stocks-with-biggest-upside-potential-1681595/ https://www.insidermonkey.com/blog/11-best-high-short-interest-stocks-with-biggest-upside-potential-1681595/"  
[X Link](https://x.com/anyuser/status/2016509531870671173)  2026-01-28T13:51Z [--] followers, [--] engagements


"$apls https://press.spglobal.com/index.phps=2429&item=136445 https://press.spglobal.com/index.phps=2429&item=136445"  
[X Link](https://x.com/oneortwo1234/status/2016335492988514686)  2026-01-28T02:20Z [--] followers, [--] engagements


"$apls Apellis added to S&P 600"  
[X Link](https://x.com/anyuser/status/2016335870274461840)  2026-01-28T02:21Z [--] followers, [--] engagements


"$ocul Ocular Therapeutix faces looming test of a more durable eye treatment via @statnews https://www.statnews.com/2026/01/08/ocular-therapeutix-wet-amd-axpaxli/ https://www.statnews.com/2026/01/08/ocular-therapeutix-wet-amd-axpaxli/"  
[X Link](https://x.com/oneortwo1234/status/2009251060896964644)  2026-01-08T13:09Z [--] followers, [---] engagements


"$ocul [--] Clinical Readouts to Watch in H1 [----] https://www.biospace.com/drug-development/5-clinical-readouts-to-watch-in-h1-2026 https://www.biospace.com/drug-development/5-clinical-readouts-to-watch-in-h1-2026"  
[X Link](https://x.com/anyuser/status/2008171843149086732)  2026-01-05T13:40Z [--] followers, [---] engagements


"$ocul What to keep an eye on in [----] https://glance.eyesoneyecare.com/stories/2026-01-02/what-to-keep-an-eye-on-in-2026/ https://glance.eyesoneyecare.com/stories/2026-01-02/what-to-keep-an-eye-on-in-2026/"  
[X Link](https://x.com/anyuser/status/2007186177225552323)  2026-01-02T20:24Z [--] followers, [---] engagements


"https://www.insidermonkey.com/blog/bofa-bullish-on-ocular-therapeutix-ocul-as-axpaxli-targets-superiority-label-and-faster-regulatory-path-in-wet-amd-1667804/ https://www.insidermonkey.com/blog/bofa-bullish-on-ocular-therapeutix-ocul-as-axpaxli-targets-superiority-label-and-faster-regulatory-path-in-wet-amd-1667804/"  
[X Link](https://x.com/oneortwo1234/status/2006408228100321551)  2025-12-31T16:52Z [--] followers, [--] engagements


"$ocul https://www.insidermonkey.com/blog/bofa-bullish-on-ocular-therapeutix-ocul-as-axpaxli-targets-superiority-label-and-faster-regulatory-path-in-wet-amd-1667804/ https://www.insidermonkey.com/blog/bofa-bullish-on-ocular-therapeutix-ocul-as-axpaxli-targets-superiority-label-and-faster-regulatory-path-in-wet-amd-1667804/"  
[X Link](https://x.com/oneortwo1234/status/2006407278597980464)  2025-12-31T16:49Z [--] followers, [---] engagements


"$ocul On December [--] [----] Ocular Therapeutix announced it will enter a quiet period starting December [--] [----] as it prepares for database lock of its SOL-1 Phase [--] clinical trial of AXPAXLI https://www.theglobeandmail.com/investing/markets/stocks/OCUL-Q/pressreleases/36722510/ocular-therapeutix-enters-quiet-period-ahead-of-sol-1-milestone/ https://www.theglobeandmail.com/investing/markets/stocks/OCUL-Q/pressreleases/36722510/ocular-therapeutix-enters-quiet-period-ahead-of-sol-1-milestone/"  
[X Link](https://x.com/anyuser/status/2003866113038504400)  2025-12-24T16:31Z [--] followers, [---] engagements


"$apls "we have not seen any side effects due to Syfovre." This interview is huge We all know that Syfovre is more effective than Izervay but there was always a cloud surrounding potential side effects. This interview puts that notion to rest. https://europe.ophthalmologytimes.com/view/q-a-jay-chhablani-discusses-analysis-of-retinal-vasculitis-events-with-intravitreal-agents https://europe.ophthalmologytimes.com/view/q-a-jay-chhablani-discusses-analysis-of-retinal-vasculitis-events-with-intravitreal-agents"  
[X Link](https://x.com/anyuser/status/1989777906911039503)  2025-11-15T19:29Z [--] followers, [--] engagements


"$apls "since October [----] the last case of retinal vasculitis which was reported due to Syfovre that was the last case. And after that there have been no events.""  
[X Link](https://x.com/anyuser/status/1989787303091605755)  2025-11-15T20:07Z [--] followers, [--] engagements


"$apls" We believed that you know this could be related to the needle which they changed it. And since then we have not seen any side effects due to Syfovre. And I have been using both complement inhibitors very confidently and I have not seen any side effects in my patients.""  
[X Link](https://x.com/anyuser/status/1989787305435857044)  2025-11-15T20:07Z [--] followers, [--] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing